Compare Abercrombie & Fitch Co. (ANF) vs Biogen Inc (BIIB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abercrombie & Fitch Co. vs Biogen Inc — how do they compare? Abercrombie & Fitch Co. trades at $113.5 (market cap $5.24B), while Biogen Inc trades at $206.52 (market cap $30.13B). The key difference: Biogen Inc is far larger — about 5.8× Abercrombie & Fitch Co.'s market cap, and Biogen Inc is trading nearer its 52-week high, Abercrombie & Fitch Co. nearer its low. Which is the better fit depends on your goals.
| ANF | BIIB | |
|---|---|---|
Market Cap | $5.24B | $30.13B |
Sector | Consumer Cyclical | Health |
52-Week High | $129.85 | $216.63 |
52-Week Low | $65.61 | $128.93 |
Enterprise Value | $5.91B | $37.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ANF trades at $114.45, down 3.44% over 24 hours, with a bullish technical signal from moving averages but bearish oscillators. The stock shows strong fundamentals with a P/E of 11.41, net income margin of 9.34%, and three consecutive quarterly EPS beats. Revenue grew to $4.95 billion in 2025, up from $4.3 billion in 2024, while operating cash flow reached $710.38 million. Recent news highlights institutional buying and an upcoming Q2 2026 earnings report on August 26, 2026.
Outlook is mixed: valuation metrics appear attractive, and earnings momentum supports upside, but overbought RSI levels and competitive retail headwinds pose risks. Analyst consensus is a $112.86 price target with 35.71% buy ratings, suggesting cautious optimism amid near-term volatility.
Biogen (BIIB) trades at $207.13, down 0.39% on the day, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings of $3.60 per share beat estimates, driven by growth in Alzheimer's and rare disease portfolios, though revenue growth remains modest. The company completed the acquisition of RayThera Inc. in August 2026, enhancing its immunology pipeline. Cash flow from operations remains healthy at $2.20 billion for 2025, supporting strategic investments.
The outlook is positive with a consensus price target of $234.47, implying ~13% upside, but risks include competitive pressures in multiple sclerosis drugs and execution challenges from recent acquisitions. Net income margin compression to 8.32% in 2026 warrants monitoring, though institutional buying and bullish analyst ratings (62.5% Buy) signal confidence in the turnaround story.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abercrombie & Fitch Co.
Abercrombie & Fitch Co is a specialty retailer that sells casual clothing, personal-care products, and accessories for men, women, and children. It sells direct to consumer through its stores and websites, which include the Abercrombie & Fitch, Abercrombie kids, and Hollister brands. Most stores are in the United States, but the company does have many stores in Canada, Europe, and Asia. All stores are leased. Abercrombie ships to well over 100 countries via its websites. The company sources its merchandise from dozens of vendors that are primarily located in Asia and Central America. Abercrombie has two distribution centers in Ohio to support its North American operations. It uses third-party distributors for sales in Europe and Asia.
Read more on ANF →About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →
